CORT Quote, Financials, Valuation and Earnings

Ironwood Pharmaceuticals has a net margin of 16.9% compared to Corcept Therapeutics's net margin of 3.52%. Corcept Therapeutics's return on equity of 23.78% beat Ironwood Pharmaceuticals's return on equity of --.

Corcept Therapeutics has a consensus price target of $143.25, signalling upside risk potential of 112.44%. On the other hand Ironwood Pharmaceuticals has an analysts' consensus of $6.00 which suggests that it could grow by 826.07%. Given that Ironwood Pharmaceuticals has higher upside potential than Corcept Therapeutics, analysts believe Ironwood Pharmaceuticals is more attractive than Corcept Therapeutics.

Corcept Therapeutics has a beta of 0.145, which suggesting that the stock is 85.456% less volatile than S&P 500. In comparison Ironwood Pharmaceuticals has a beta of 0.297, suggesting its less volatile than the S&P 500 by 70.281%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ironwood Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Ironwood Pharmaceuticals pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $181.9M, which are larger than Ironwood Pharmaceuticals quarterly revenues of $90.5M. Corcept Therapeutics's net income of $30.7M is higher than Ironwood Pharmaceuticals's net income of $3.2M. Notably, Corcept Therapeutics's price-to-earnings ratio is 54.38x while Ironwood Pharmaceuticals's PE ratio is 126.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 11.34x versus 0.30x for Ironwood Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 16.9% compared to Corcept Therapeutics's net margin of -117.16%. Corcept Therapeutics's return on equity of 23.78% beat Moderna's return on equity of -29.09%.

Corcept Therapeutics has a consensus price target of $143.25, signalling upside risk potential of 112.44%. On the other hand Moderna has an analysts' consensus of $51.31 which suggests that it could grow by 91.45%. Given that Corcept Therapeutics has higher upside potential than Moderna, analysts believe Corcept Therapeutics is more attractive than Moderna.

Corcept Therapeutics has a beta of 0.145, which suggesting that the stock is 85.456% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $181.9M, which are smaller than Moderna quarterly revenues of $956M. Corcept Therapeutics's net income of $30.7M is higher than Moderna's net income of -$1.1B. Notably, Corcept Therapeutics's price-to-earnings ratio is 54.38x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 11.34x versus 3.25x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 16.9% compared to Corcept Therapeutics's net margin of 24.89%. Corcept Therapeutics's return on equity of 23.78% beat Nektar Therapeutics's return on equity of -133.07%.

Corcept Therapeutics has a consensus price target of $143.25, signalling upside risk potential of 112.44%. On the other hand Nektar Therapeutics has an analysts' consensus of $4.92 which suggests that it could grow by 714.15%. Given that Nektar Therapeutics has higher upside potential than Corcept Therapeutics, analysts believe Nektar Therapeutics is more attractive than Corcept Therapeutics.

Corcept Therapeutics has a beta of 0.145, which suggesting that the stock is 85.456% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.381%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $181.9M, which are larger than Nektar Therapeutics quarterly revenues of $29.2M. Corcept Therapeutics's net income of $30.7M is higher than Nektar Therapeutics's net income of $7.3M. Notably, Corcept Therapeutics's price-to-earnings ratio is 54.38x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 11.34x versus 1.26x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals has a net margin of 16.9% compared to Corcept Therapeutics's net margin of 8.8%. Corcept Therapeutics's return on equity of 23.78% beat Supernus Pharmaceuticals's return on equity of 7.61%.

Corcept Therapeutics has a consensus price target of $143.25, signalling upside risk potential of 112.44%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $38.80 which suggests that it could grow by 22.79%. Given that Corcept Therapeutics has higher upside potential than Supernus Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Supernus Pharmaceuticals.

Corcept Therapeutics has a beta of 0.145, which suggesting that the stock is 85.456% less volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.882%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $181.9M, which are larger than Supernus Pharmaceuticals quarterly revenues of $174.2M. Corcept Therapeutics's net income of $30.7M is higher than Supernus Pharmaceuticals's net income of $15.3M. Notably, Corcept Therapeutics's price-to-earnings ratio is 54.38x while Supernus Pharmaceuticals's PE ratio is 23.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 11.34x versus 2.67x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.